增强肝脏中胆色素原脱氨酶（PBGD）的表达作为急性间歇性卟啉症的一种新型基因疗法（AIP基因）。 - Suppr | 超能文献

Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene).

出版信息

Hum Gene Ther Clin Dev. 2014 Jun;25(2):61-3. doi: 10.1089/humc.2014.2506.

DOI:10.1089/humc.2014.2506

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Augmenting PBGD expression in the liver as a novel gene therapy for acute intermittent porphyria (AIPgene).增强肝脏中胆色素原脱氨酶（PBGD）的表达作为急性间歇性卟啉症的一种新型基因疗法（AIP基因）。

Hum Gene Ther Clin Dev. 2014 Jun;25(2):61-3. doi: 10.1089/humc.2014.2506.

2

Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.辅助依赖性腺相关病毒肝基因治疗可预防急性间歇性卟啉症小鼠的发作，并纠正蛋白折叠应激。

Hum Mol Genet. 2013 Jul 15;22(14):2929-40. doi: 10.1093/hmg/ddt148. Epub 2013 Apr 5.

3

An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria.可响应不同卟啉生成刺激的诱导型启动子可改善急性间歇性卟啉症的基因治疗载体。

Hum Gene Ther. 2018 Apr;29(4):480-491. doi: 10.1089/hum.2017.056. Epub 2018 Jan 2.

4

Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.腺病毒介导的肝脏中胆色素原脱氨酶表达可恢复急性间歇性卟啉症小鼠模型的代谢缺陷。

Mol Ther. 2004 Aug;10(2):337-43. doi: 10.1016/j.ymthe.2004.05.018.

5

Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria.rAAV5 - 共表达人胆色素原脱氨酶在非人灵长类动物中的安全性和肝脏转导效率：急性间歇性卟啉症的一种潜在治疗方法

Hum Gene Ther. 2013 Dec;24(12):1007-17. doi: 10.1089/hum.2013.166.

6

Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.肝细胞中卟啉原脱氨酶的过度表达，但不在红细胞中，可防止急性间歇性卟啉症小鼠模型中有毒卟啉前体的积累。

J Hepatol. 2010 Mar;52(3):417-24. doi: 10.1016/j.jhep.2009.09.003. Epub 2009 Sep 23.

7

Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.将胆色素原脱氨酶互补脱氧核糖核酸以非病毒方式导入急性间歇性卟啉症小鼠模型。

Mol Genet Metab. 2004 May;82(1):20-6. doi: 10.1016/j.ymgme.2004.02.008.

8

Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.实验性胆色素原脱氨酶缺乏症会改变禁食期间的葡萄糖代谢。

Hum Mol Genet. 2016 Apr 1;25(7):1318-27. doi: 10.1093/hmg/ddw013. Epub 2016 Jan 21.

9

Acute intermittent porphyria: vector optimization for gene therapy.急性间歇性卟啉症：基因治疗的载体优化

J Gene Med. 2007 Sep;9(9):806-11. doi: 10.1002/jgm.1074.

10

Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.生物工程化 PBGD 变体提高急性间歇性卟啉症基因治疗载体的治疗指数。

Hum Mol Genet. 2018 Nov 1;27(21):3688-3696. doi: 10.1093/hmg/ddy283.

引用本文的文献

1

An update of clinical management of acute intermittent porphyria.急性间歇性卟啉症临床管理的最新进展。

Appl Clin Genet. 2015 Sep 1;8:201-14. doi: 10.2147/TACG.S48605. eCollection 2015.